Abstract: The present invention provides polymer micelles with cross-linked ionic cores as delivery vehicles for therapeutics, diagnostics, nucleic acids, proteins, small molecules and the like. The present invention provides additionally methods of synthesis and uses for such micelles.

Abstract: The present invention relates to a cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough. The cough depressant composition of the present invention comprises 0.01-100% by weight of Fe2+(ferrous) or Fe3+(ferric). Furthermore, the cough depressant composition of the present invention can comprise an angiotensin-converting enzyme inhibitor. The cough depressant composition of the present invention relieves the pain of the patient by reducing continuous dry cough.

Abstract: A particle (and a composition that includes a plurality of the particles) that includes at least one polypeptide molecule and at least one polymer covalently bound to the polypeptide molecule so as to form a polymer shell substantially encompassing the polypeptide molecule, wherein the particle does not define a dimension greater than about 1 ?m. One example for making the particle includes modifying the polypeptide molecule to provide ?, ?-ethylenically unsaturated terminal functional groups, mixing the modified polypeptide molecule with a silicon-containing polymerizable compound, and subjecting the resulting mixture to conditions sufficient for polymerizing the polymerizable compound to form the particle.

Abstract: The present invention is related to a solid pharmaceutical composition comprising two separate regions, a first region comprising at least one non-steroidal anti-inflammatory drug (NSAID) and an adequate pharmaceutical carrier containing a retardant material for an extended release delivery of said non-steroidal anti-inflammatory drug (NSAID), and a second region comprising a stabilized gastroprotective prostaglandin and an adequate pharmaceutical carrier for an immediate release of said stabilized gastroprotective prostaglandin.

Abstract: Skin care compositions and methods for regulating the condition of mammalian keratinous tissue containg an effective amount of a dialkanoyl hydroxyproline compound and a second skin care compound selected from hexamidine compounds, sugar amine compounds and their combination. These compositions may be either an emulsion or a solution wherin the dialkanoyl hydroxyproline compound may be converted to its salt for incorporation into the aqueous phase of a compositions.

Abstract: A graft reverse thermal hydrogel which does not show substantial loss of complex viscosity at and up to 20 degrees above the transition temperature upon autoclaving or aging. Other embodiments include the graft reverse thermal copolymer which can be dissolved in water to produce the graft reverse thermal hydrogel, a process for manufacturing the graft reverse thermal copolymer and hydrogel and applications for the stable graft reverse thermal hydrogel.

Abstract: The invention describes pharmaceutical preparations with retarding active ingredient release, which consist of mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant. The pharmaceutical preparations are used as permanent or as temporary implants in the form of tablets, molded bodies, fibers and granules.

Abstract: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed throughout the particles, wherein the active material(s) is capable of being released from said particles, and the active material(s) in said particles is substantially protected from degradation until release of the active material(s) from the particles.

Abstract: This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon's routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods.

Abstract: Disclosed are an organic domain/inorganic domain hybrid material comprising an organic domain comprising at least one water-soluble organic polymer having anionic and/or cationic functional groups, and an inorganic domain, the organic and inorganic domains being chemically bonded to each other through the functional groups, the inorganic domain comprising inorganic bridges, each independently comprising at least one Si atom, at least two O atoms and at least one divalent metal atom, wherein the Si atom and the O atoms together form at least one siloxane linkage arranged longitudinally of the inorganic bridge, wherein each divalent metal atom is ionically bonded to the O atoms of the siloxane linkages positioned adjacent to the divalent metal atoms, wherein, when at least a part of the organic domain is comprised of at least one organic polymer having an anionic functional group and optionally a cationic functional group, the organic domain/inorganic domain weight ratio is less than 1.

Abstract: End-capped polymers, methods for making those end-capped polymers and compositions containing those end-capped polymers are disclosed. One of the disclosed end-capped copolymers has the formula: and may be combined with demineralized bone particles to form a tissue repair composition.

Abstract: A towelette product is provided which includes a first water-insoluble substrate having dorsal and ventral surfaces, a second water-insoluble substrate having dorsal and ventral surfaces, the dorsal surfaces of the first and second substrates being joined to one another. A personal care composition is deposited onto an area of the second ventral surface, the first ventral surface having a dry-to-the-touch feel, the second ventral surface on the deposit area having a non-dry-to-the-touch feel, the first ventral surface having a FTV of not higher than 0.1 grams.

Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.

Abstract: A stretch plaster comprising a support membrane having a thickness of 1 to 50 ?m and a drug containing adhesive layer having a thickness of 3 to 400 ?m, wherein (i) the support membrane comprising a copolymer of 0 to 90% by weight of vinyl acetate, 10 to 97% by weight of alkyl (meth)acrylate having 3 to 14 of a mean carbon number of alkyl group and 0 to 15% by weight of (meth)acrylic acid, (ii) the copolymer is cross-linked by polyvalent metal such as aluminum or a poly-functional chain compound, wherein the cross-linking ratio is 20% or more of the theoretical total number of carboxyl group of the copolymer when the polymer is cross-linked by the polyvalent metal such as aluminum, and is 1 to 10% expressed by copolymerized ratio of the poly-functional chain compound when the copolymer is cross-linked by poly-functional chain compound, (iii) the support membrane has 150 g or less of self adhesion shown by an adhesion between the support membranes and (iv) the support membrane has 70% or more of an elasticit

Abstract: Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic membrane in a flowable form and, after delivery to the tympanic membrane, becomes sufficiently viscous such that the pharmacologic agent is localized against the tympanic membrane. Such compositions can be used to prophylactically and/or therapeutically treat middle and inner ear conditions, including otitis media.

Abstract: The present invention is directed to parenterally-administrable microparticles for providing sustained-release of a therapeutic agent in the body, where the microparticles include a polymeric core containing a therapeutically effective amount of a therapeutic agent disposed therein, a first film encapsulating the core, the first film prepared from a first biodegradable polymer soluble in an appropriate solvent therefore, and a second film encapsulating the core and the first film, the second film prepared from a biodegradable polymer soluble in an appropriate solvent therefore, wherein the first film is insoluble in the solvent used to prepare the second film, and to parenterally-administrable compositions containing such microparticles dispersed in a suitable carrier therefore.

Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: End-capped polymers, methods for making those end-capped polymers, compositions containing those end-capped polymers, and methods for using those compositions are disclosed. One of the disclosed end-capped copolymers has the formula (I): and may be combined with natural or synthetic bone minerals, bone tissue, collagen tissue, bone protein or combinations or derivatives of those materials to form a tissue repair composition.

Abstract: A treatment for dry eye and other eye problems using a plug system or a delivery system. The plug system comprises solid, porous or hollow microcapsules composed of a biodegradable biocompatible polymer. The capsules are stored in the form of a powder that can be suspended in an aqueous carrier solution or dispersed in a gel or an ointment. Alternatively a biodegradable biocompatible capsule having a treating agent encapsulated within a polymer shell or a polymer sphere, again stored in the form of a powder that can be suspended in an aqueous carrier solution or dispersed in a gel or an ointment. The plug system prevents excretion of the capsules and their size is larger then the punctum and to prevent entrance to the lachrymal excretory system. The treatment is slowly released into the eye through the polymer shell or sphere and/or gets secreted as the polymer degrades.

Abstract: The method of the production of a nanoparticle of the present invention includes a step of forming a nanoparticle including a compound of ametal ion in a cavity part of aprotein, in a solution containing the protein having the cavity part therein, the metal ion, and a carbonate ion and/or a hydrogen carbonate ion. Examples of the aforementioned compound include e.g., a hydroxide. The aforementioned metal ion is preferably any one of a nickel ion (Ni2+), a chromium ion (Cr2+) or a copper ion (Cu2+). According to the aforementioned method, nanoparticles having a uniform particle diameter can be produced.